Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Hot Flashes 1

Interventions

Carboplatin 127pembrolizumab 123Cisplatin 112Paclitaxel 102Gemcitabine 83Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 69Dexamethasone 59Cyclophosphamide 59Pemetrexed 54Bevacizumab 54Doxorubicin 52durvalumab 51Radiotherapy 49Capecitabine 48Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 39Etoposide 38atezolizumab 35Nivolumab 35Letrozole 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Aromatase Inhibitors × 90 days × Clear all
NCT05879926 2026-06-03

OFSET

NRG Oncology

Phase 3 Recruiting
3,960 enrolled
Breast

Breast Neoplasms

NCT07400523 2026-04-28

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
446 enrolled
Breast

Breast Neoplasms

NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Astellas Pharma Inc

Phase 3 Active not recruiting
984 enrolled

Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡